New York State Teachers Retirement System Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR)

New York State Teachers Retirement System lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 59,411 shares of the biotechnology company's stock after buying an additional 3,607 shares during the period. New York State Teachers Retirement System owned about 0.13% of United Therapeutics worth $21,290,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. GW Henssler & Associates Ltd. bought a new position in United Therapeutics in the 3rd quarter valued at approximately $255,000. China Universal Asset Management Co. Ltd. raised its stake in shares of United Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,557 shares of the biotechnology company's stock valued at $3,066,000 after acquiring an additional 3,344 shares during the last quarter. Pallas Capital Advisors LLC lifted its holdings in shares of United Therapeutics by 62.5% during the third quarter. Pallas Capital Advisors LLC now owns 1,895 shares of the biotechnology company's stock worth $664,000 after purchasing an additional 729 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of United Therapeutics by 4.0% in the third quarter. Nisa Investment Advisors LLC now owns 22,779 shares of the biotechnology company's stock worth $8,163,000 after purchasing an additional 870 shares during the last quarter. Finally, FCG Investment Co acquired a new stake in United Therapeutics in the third quarter valued at $1,637,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. LADENBURG THALM/SH SH lifted their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday. The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a report on Friday. Bank of America lowered their price target on shares of United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a report on Thursday, August 1st. UBS Group upped their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the company a "buy" rating in a research note on Monday, July 8th. Finally, Jefferies Financial Group lifted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $370.86.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of the business's stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the completion of the sale, the chief financial officer now directly owns 6,978 shares of the company's stock, valued at approximately $2,442,300. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO James Edgemond sold 7,800 shares of the company's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the sale, the chief financial officer now owns 6,978 shares in the company, valued at $2,442,300. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 25,000 shares of the firm's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $833,350.26. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 98,412 shares of company stock worth $33,971,508 in the last quarter. Insiders own 11.90% of the company's stock.

United Therapeutics Stock Up 0.0 %

NASDAQ:UTHR traded up $0.05 on Friday, hitting $374.02. The stock had a trading volume of 426,943 shares, compared to its average volume of 319,868. The company has a market cap of $16.70 billion, a PE ratio of 16.43, a P/E/G ratio of 1.35 and a beta of 0.56. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $377.92. The business's fifty day moving average is $355.40 and its 200 day moving average is $316.65.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the previous year, the business posted $5.38 EPS. United Therapeutics's quarterly revenue was up 22.9% on a year-over-year basis. Equities analysts predict that United Therapeutics Co. will post 24.85 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.